Autologous NK Cell Therapy (Federal Research Institute of Pediatric Hematology Oncology and Immunology)

N/A

Report date: 2026/01/30 20:01:05

Base Information

Drug NameAutologous NK Cell Therapy (Federal Research Institute of Pediatric Hematology Oncology and Immunology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsGanglioneuroblastomaNeuroblastomaLeukemia, Myeloid, Acute +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesFederal Research Institute of Pediatric Hematology Oncology and Immunology
China Registration ClassN/A

Develop Information

Active CompaniesFederal Research Institute of Pediatric Hematology Oncology and Immunology
Inactive CompaniesN/A
Active IndicationsGanglioneuroblastomaNeuroblastomaLeukemia, Myeloid, Acute +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A